{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:28:17Z","timestamp":1791318497886,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.beem.2004.11.016","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T11:20:28Z","timestamp":1110540028000},"page":"265-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours"],"prefix":"10.1016","volume":"19","author":[{"given":"Kjell","family":"\u00d6berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbro","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"supplement 2","key":"10.1016\/j.beem.2004.11.016_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/10.suppl_2.S3","article-title":"Neuroendocrine gastrointestinal tumors\u2014a condensed overview of diagnosis and treatment","volume":"10","author":"Oberg","year":"1999","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beem.2004.11.016_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour","volume":"352","author":"Caplin","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2004.11.016_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s001090050233","article-title":"Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors","volume":"76","author":"Rindi","year":"1998","journal-title":"Journal of Molecular Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib4","first-page":"71","article-title":"Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin","volume":"170","author":"Pearse","year":"1968","journal-title":"Proceedings of the Royal Society of London Series Biological Sciences"},{"key":"10.1016\/j.beem.2004.11.016_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/17.5.303","article-title":"The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept","volume":"17","author":"Pearse","year":"1969","journal-title":"Journal of Histochemistry and Cytochemistry"},{"key":"10.1016\/j.beem.2004.11.016_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00256489","article-title":"The role of I-131-MIBG in the diagnosis and therapy of carcinoids","volume":"13","author":"Hoefnagel","year":"1987","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/02841869309083911","article-title":"Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors","volume":"32","author":"Eriksson","year":"1993","journal-title":"Acta oncologica"},{"key":"10.1016\/j.beem.2004.11.016_bib8","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1073\/pnas.90.9.4196","article-title":"Cloning and characterization of a fourth human somatostatin receptor","volume":"90","author":"Rohrer","year":"1993","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"10.1016\/j.beem.2004.11.016_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1006\/bbrc.1994.1088","article-title":"All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase","volume":"198","author":"Patel","year":"1994","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.beem.2004.11.016_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0026-0495(90)90217-Z","article-title":"Distribution of somatostatin receptors in normal and tumor tissue","volume":"39","author":"Reubi","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2004.11.016_bib11","first-page":"5801s","article-title":"Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers","volume":"55","author":"Kalkner","year":"1995","journal-title":"Cancer Research"},{"key":"10.1016\/j.beem.2004.11.016_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/02841869309096136","article-title":"Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide","volume":"32","author":"Westlin","year":"1993","journal-title":"Acta oncologica"},{"key":"10.1016\/j.beem.2004.11.016_bib13","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/0024-3205(91)90052-D","article-title":"[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation","volume":"49","author":"Bakker","year":"1991","journal-title":"Life Sciences"},{"key":"10.1016\/j.beem.2004.11.016_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF03345484","article-title":"Receptor imaging in the diagnosis and treatment of pituitary tumors","volume":"22","author":"Kwekkeboom","year":"1999","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2004.11.016_bib15","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib17","first-page":"539","article-title":"Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas","volume":"40","author":"Gibril","year":"1999","journal-title":"Journal of Nuclear Mediciine"},{"key":"10.1016\/j.beem.2004.11.016_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0969-8051(99)00085-2","article-title":"Demonstration of [11C] 5-hydroxy-l-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography","volume":"27","author":"Sundin","year":"2000","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.beem.2004.11.016_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","article-title":"Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors","volume":"220","author":"Hoegerle","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.beem.2004.11.016_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","article-title":"Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours","volume":"25","author":"Adams","year":"1998","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib21","article-title":"Carbidopa pretreatment improves image interpretation and visualization of neuroendocrine tumors with 11C-5-HTP-PET","author":"Orlefors","year":"2005","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jcem.86.2.7194","article-title":"Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors","volume":"86","author":"Kaltsas","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2004.11.016_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Seminars in Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beem.2004.11.016_bib27","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib28","first-page":"100","article-title":"Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?","volume":"29","author":"Waldherr","year":"2002","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bip.10349","article-title":"90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies","volume":"66","author":"Paganelli","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/j.beem.2004.11.016_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2004.11.016_bib31","first-page":"232","article-title":"Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0,Tyr3]octreotide in patients with somatostatin receptor positive tumours","volume":"30","author":"Valkema","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2004.11.016_bib32","first-page":"437","article-title":"Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy","volume":"58","author":"de Jong","year":"1998","journal-title":"Cancer Research"},{"key":"10.1016\/j.beem.2004.11.016_bib33","first-page":"223","article-title":"High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model","volume":"40","author":"Erion","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"European Journal of Nuclear Medicine"},{"key":"10.1016\/j.beem.2004.11.016_bib35","first-page":"231","article-title":"Treatment with Lu-177-DOTA-Tyr3-Octreotate in patients with neuroendocrine tumors: interim results","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.beem.2004.11.016_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"De Jong","year":"2002","journal-title":"Seminars in Nuclear Medicine"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X04000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X04000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:35:13Z","timestamp":1761496513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X04000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1521690X04000946"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2004.11.016","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2004.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}